Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan;23(1):95-109.
doi: 10.1016/S1474-4422(23)00377-0.

Blood-brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies

Affiliations
Review

Blood-brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies

Bettina Zierfuss et al. Lancet Neurol. 2024 Jan.

Abstract

Established by brain endothelial cells, the blood-brain barrier (BBB) regulates the trafficking of molecules, restricts immune cell entry into the CNS, and has an active role in neurovascular coupling (the regulation of cerebral blood flow to support neuronal activity). In the early stages of multiple sclerosis, around the time of symptom onset, inflammatory BBB damage is accompanied by pathogenic immune cell infiltration into the CNS. In the later stages of multiple sclerosis, dysregulation of neurovascular coupling is associated with grey matter atrophy. Genetic and environmental factors associated with multiple sclerosis, including dietary habits, the gut microbiome, and vitamin D concentrations, might contribute directly and indirectly to brain endothelial cell dysfunction. Damage to brain endothelial cells leads to an influx of deleterious molecules into the CNS, accelerating leakage across the BBB. Potential future therapeutic approaches might help to prevent BBB damage (eg, monoclonal antibodies targeting cell adhesion molecules and fibrinogen) and help to repair BBB dysfunction (eg, mesenchymal stromal cells) in people with multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests BZ was supported by a joint Fonds de recherche Québec—Santé (FRQS)–Multiple Sclerosis Society of Canada fellowship. CL is an FRQS Clinicien–Chercheur Junior 2 Scholar; has served on scientific advisory boards for FIND Therapeutics, Novartis, Biogen, Sanofi, Bristol Myers Squibb, and Actelion; has served as a speaker for Novartis, Biogen, Sanofi, Roche, and EMD Serono; and has received a grant for Multiple Sclerosis Innovation from Merck–EMD Serono. AP holds the Senior Canada Research Chair in Multiple Sclerosis and active patents WO2016095046A1, US20110014183A1, and US20100310568A1.

Publication types

LinkOut - more resources